RAN080 (vs atenolol) 2005

1 Treatments

Studied treatment  ranolazine IR 400mg TID

Control treatment

Concomittant treatments

2 Patients

Patients  patients who had symptom-limited exercise

Inclusion criteria

Exclusion criteria

3 Methods

Blinding  double blind

Design  -

Centers  -

Geographical area  Europe, canada

Sizes  158/0

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Death from any cause</td>
<td>-/158</td>
<td>-/0</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>angina frequency (per week)</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

5 References